Adverse Reactions to Factor VIII Infusions

Eyster, M. Elaine; Bowman, Herbert S.; Haverstick, Judy

doi:10.7326/0003-4819-87-2-248_1

Cited by 27 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, the ICs may result from sensitization to various plasma protein alloantigens. Anaphylactoid reactions to plasma concentrates are not uncommon in some series [19], and on occasion have been traced to incompatibilities of beta-lipoproteins [20] and, more commonly, to Gm and Inv alloantigens of immunoglobulins [21,22] . This latter observation may explain the 35% incidence of weakly positive rheumatoid factor activity which we observed in our hemophilia A Despite these predisposing factors for IC generation and in agreement with the work population.…”

Section: Discussionmentioning

confidence: 99%

Immune complexes in hemophilia

Poskitt¹,

Poskitt²,

Bean³

et al. 1981

American J Hematol

View full text Add to dashboard Cite

Circulating immune complexes (ICs), assayed by the L1210 enzyme-linked immunoassay, were detected in 48% of patients with hemophilia. A, 50% of patients with von Willebrand's disease, and in none of our patients with hemophilia B. Eighty-five % of the hemophilia A and B patients had mild to moderate disease with only one patient demonstrating a circulating inhibitor. No correlation was found between IC levels and hepatitis B infection, SGOT, disease severity, total quantity of factor VIII or IX infused, time interval from list infusion, or rheumatoid factor positivity. Although the nature of the ICs is not known, the similarity of IC levels between hemophilia A and von Willebrand's disease is discussed with regard to antibodies generated to non-procoagulant portions of the factor VIII molecule.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune complexes in hemophilia

Poskitt¹,

Poskitt²,

Bean³

et al. 1981

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Transfusion disease is complicated by the development of anti‐Factor VIII C antibodies. Inhibitors to Factor VIII C arise in 5–15% of transfused hemophiliacs 22 . Recent improvements in factor replacement therapy, primarily heat treated concentrates, have eliminated the risk of viral transmission by transfusion 23…”

Section: Discussionmentioning

confidence: 99%

Mild Hemophilia A as a Cause of Bleeding in Dermatologic Surgery

Clark

Zurowski²

1988

The Journal of Dermatologic Surgery and Oncology

View full text Add to dashboard Cite

A 63-year-old male had major postoperative bleeding complications following the excision of a basal cell carcinoma. The patient denied a prior history of bleeding complications and had normal coagulation screening studies. After coagulation evaluation, he was found to have mild hemophilia A with 23% of normal Factor VIII C. We discuss an approach to the evaluation of coagulation in patients with perioperative and postoperative bleeding. Also, we outline treatment alternatives for patients with hemophilia A who need cutaneous surgery.

show abstract

“…Eyster et al 7 reported adverse reaction rates of 19% in their series of HA patients receiving freeze-dried concentrates and cryoprecipitate, the reactions varying from fever and hypersensitivity phenomena to severe anaphylactic shock. Allergic reactions have also been reported in patients receiving porcine factor VIII.…”

Section: Anaphylaxis In Hemophilia Amentioning

confidence: 99%

Anaphylaxis in Patients with Hemophilia

Jadhav¹,

Warrier²

2000

Semin Thromb Hemost

View full text Add to dashboard Cite

Anaphylactic reactions are rare emergencies observed in hemophilia patients. In hemophilia (B) (HB) patients they typically occur coincident with the development of an inhibitor. It is important to be aware of the possibility of such reactions, and the patient's family should be educated at the time of initial diagnosis and discussion. Because these reactions typically occur within the first 10 to 20 treatment courses, the first few infusions should be given in a hospital/clinic setting equipped to manage such emergencies. Obtaining the exact genotype may identify the HB patients at risk for this complication. When immune tolerance induction (ITI) is attempted in patients with HB inhibitors and anaphylaxis, the physician should be vigilant in detecting proteinuria.

show abstract

Adverse Reactions to Factor VIII Infusions

Cited by 27 publications

References 0 publications

Immune complexes in hemophilia

Immune complexes in hemophilia

Mild Hemophilia A as a Cause of Bleeding in Dermatologic Surgery

Anaphylaxis in Patients with Hemophilia

Contact Info

Product

Resources

About